Omkar Pharmachem Ltd.
Snapshot View

21.30 ▼0%

10 May 2022, 04:01:00 PM

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.omkarpharmachem.co.in
Market Cap 21.48 Cr.
Enterprise Value(EV) 22.34 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) 0.47 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) 45.80 Trailing Twelve Months Ending 2021-12
Industry PE 28.47 Trailing Twelve Months Ending 2021-12
Book Value / Share 8.77 Trailing Twelve Months Ending 2021-12
Price to Book Value 2.43 Calculated using Price: 21.30
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 1.01 Cr. 10,084,800 Shares
FaceValue 10
Company Profile

Omkar Pharmachem was incorporated in 1994, it is located in New Delhi. The manufacturing unit developed the capacity to manufacture sodium bi-sulphite, sodium meta bi-sulphite, sodium sulphite, and sulphur.

In the financial year 2007, the company did not conduct any manufacturing or other business activity due to tough market conditions. It has further decided to discontinue commercial activity and wait till an appropriate business environment is established.

The registered office of the company is located at Mahakant Building, 501, Ashram Road opposite V S Hospital Ellisbridge Ahmedabad, Gujarat 380006.

Business area of the company

The company is engaged in the manufacturing of pharmaceutical chemicals.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
1 Week
1 Month
+10.08%
3 Month
-10.13%
6 Month
-6.17%
1 Year
+12.11%
2 Year
+28.31%
5 Year
+141.50%
10 Year
+285.87%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) -0.13 0.04 -0.66 -1.27 2.38 -2.77 -4.72 -3.03 2.59
Return on Capital Employed (%) -0.13 0.04 -0.66 -1.27 2.91 -2.55 -4.11 -2.22 0.22
Return on Assets (%) -0.13 0.04 -0.65 -1.22 2.30 -2.72 -4.49 -2.78 2.36

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 9 9 9 9 9 9 9 8 9 9
Non Curr. Liab. 0 0 0 0 0
Curr. Liab. 0 0 0 1 0 0 1 1 1 1
Minority Int.
Equity & Liab. 9 9 9 10 9 9 9 9 9 9
Non Curr. Assets 9 9 9 9 9 9 9 9 9 9
Curr. Assets 0 0 0 0 0 0 0 0 0 0
Misc. Exp. not W/O
Total Assets 9 9 9 10 9 9 9 9 9 9

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 0 0 0 0 1
Other Income 0
Total Income 0 0 0 0 0 1
Total Expenditure 0 0 0 0 0 0 0 0 0 0
PBIDT 0 0 0 0 0 0 0 0 0
Interest 0 0 0 0 0
Depreciation
Taxation 0 0 0
Exceptional Items 0
PAT 0 0 0 0 0 0 0 0 0
Adjusted EPS 0 0 0 0 0 0 0 0 0

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 0 0 0 0 0 -1 0 0 0 0
Cash Fr. Inv. 0 0 0
Cash Fr. Finan. 0 0 0 0 0 0
Net Change 0 0 0 0 0 0 0 0
Cash & Cash Eqvt 0 0 0 0 0 0 0 0 0

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03
Public 99.97 99.97 99.97 99.97 99.97 99.97 99.97 99.97 99.97
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Fri, 29 Apr 2022
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1Name of CompayOMKAR PHARMACHEM LTD.
2CINL93000GJ1995PLC025276
3 Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) 0.92
4Highest Credit Rating during the previous FY NA
4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable
5Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the frameworkBSE


We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No



Name of the Company Secretary: PANKAJ MAHADEO SINGH
Designation: COMPANY SECRETARY
EmailId: cssinghpankaj9977@gmail.com
Name of the Chief Financial Officer: GAURAV KATHURIA
Designation: CHIEF FINANCIAL OFFICER
EmailId: investors.opl@gmail.com

Date: 29/04/2022

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Wed, 20 Apr 2022
Submission Of Certificate Under Regulation 40(9) Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015
Dear Sir Please find enclosed herewith Certificate issued by the Practicing Company Secretary pursuant to regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for year ended on 31st March 2022.
Tue, 19 Apr 2022
Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- Bhawani Shankar Goyal
Designation :- Managing Director / Whole Time Director

Technical Scans View Details

No Scans Found

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 212,197.18 910.90 +3.0%
Divi's Laboratories Ltd. 111,510.08 4,301.75 +2.4%
Cipla Ltd. 75,683.19 976.70 +4.1%
Dr. Reddy's Laboratories Ltd. 65,571.78 4,245.50 +8.0%
Apollo Hospitals Enterprise Ltd. 52,245.59 3,669.25 +1.0%
Gland Pharma Ltd. 51,277.11 3,051.60 -1.6%
Piramal Enterprises Ltd. 45,274.50 1,923.95 +1.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 32.93 910.90 +3.0%
Divi's Laboratories Ltd. Consolidated 2021-12 43.43 4,301.75 +2.4%
Cipla Ltd. Consolidated 2022-03 30.07 976.70 +4.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 30.04 4,245.50 +8.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.10 3,669.25 +1.0%
Gland Pharma Ltd. Consolidated 2021-12 43.23 3,051.60 -1.6%
Piramal Enterprises Ltd. Consolidated 2021-12 36.44 1,923.95 +1.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.11 910.90 +3.0%
Divi's Laboratories Ltd. Consolidated 2021-12 10.30 4,301.75 +2.4%
Cipla Ltd. Consolidated 2022-03 3.63 976.70 +4.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.41 4,245.50 +8.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.44 3,669.25 +1.0%
Gland Pharma Ltd. Consolidated 2021-12 7.47 3,051.60 -1.6%
Piramal Enterprises Ltd. Consolidated 2021-12 1.28 1,923.95 +1.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 910.90 +3.0%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,301.75 +2.4%
Cipla Ltd. Consolidated 2021-03 0.10 976.70 +4.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,245.50 +8.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,669.25 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,051.60 -1.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,923.95 +1.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 910.90 +3.0%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,301.75 +2.4%
Cipla Ltd. Consolidated 2021-03 14.13 976.70 +4.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,245.50 +8.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,669.25 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,051.60 -1.6%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,923.95 +1.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 910.90 +3.0%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,301.75 +2.4%
Cipla Ltd. Consolidated 2021-03 14.13 976.70 +4.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,245.50 +8.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,669.25 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,051.60 -1.6%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,923.95 +1.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 910.90 +3.0%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,301.75 +2.4%
Cipla Ltd. Consolidated 2021-03 19,159.59 976.70 +4.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,245.50 +8.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,669.25 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,051.60 -1.6%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,923.95 +1.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 910.90 +3.0%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,301.75 +2.4%
Cipla Ltd. Consolidated 2021-03 2,401.30 976.70 +4.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,245.50 +8.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,669.25 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,051.60 -1.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,923.95 +1.6%